Samsung BioLogics faces criminal probe into IPO
South Korea’s financial regulator has brought the hammer down on Samsung BioLogics, accusing it of intentionally overvaluing a subsidiary ahead of its W2.25tr ($2bn) IPO in late 2016.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts